(Q38176034)

30 August 2017

title

Cytoreductive nephrectomy: past, present and future (English)

1 reference

30 August 2017

Myria Galazi

1

1 reference

30 August 2017

Alejo Rodriguez-Vida

2

1 reference

30 August 2017

Eleni Josephides

3

1 reference

30 August 2017

Noan-Minh Chau

4

1 reference

30 August 2017

Simon Chowdhury

5

1 reference

30 August 2017

publication date

6 January 2014

1 reference

Expert Review of Anticancer Therapy

30 August 2017

published in

1 reference

30 August 2017

volume

14

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

271-277

1 reference

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

The genetic basis of kidney cancer: a metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: the influence of neoadjuvant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Sunitinib for treatment of advanced renal cell cancer: primary tumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.864240

10.1586/14737140.2014.864240

21 January 2018

Identifiers

DOI

1 reference

release_v6njqnyadbebjde7gze42o3ghq

30 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/v6njqnyadbebjde7gze42o3ghq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference